Posted on December 8th, 2011 by
Computer, drug and biotechnology companies have a message for the U.S. Supreme Court as it prepares for arguments this week on patents for diagnostic medical tests: Be careful. Companies, trade groups and lawyers have filed more than two dozen legal briefs, many warning that the court’s ruling might have widespread, unintended ramifications. Each side in the case, which pits Nestle SA (NESN)’s Prometheus unit against the Mayo Clinic, says a defeat might stifle innovation.
Bloomberg, by Greg Stohr, 12/5/11
You must be logged-in to the site to post a comment.